@article{5bf0ef4aba5e4a1ebd04e81b17c04fbc,
title = "Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications",
abstract = "While the first part of the scientific statement on the pathophysiology of Takotsubo syndrome was focused on catecholamines and the sympathetic nervous system, in the second part we focus on the vascular pathophysiology including coronary and systemic vascular responses, the role of the central and peripheral nervous systems during the acute phase and abnormalities in the subacute phase, the gender differences and integrated effects of sex hormones, genetics of Takotsubo syndrome including insights from microRNA studies and inducible pluripotent stem cell models of Takotsubo syndrome. We then discuss the chronic abnormalities of cardiovascular physiology in survivors, the limitations of current clinical and preclinical studies, the implications of the knowledge of pathophysiology for clinical management and future perspectives and directions of research.",
keywords = "Takotsubo syndrome, Pathophysiology, Vascular, Nervous system, Oestrogen, Genetics, microRNA, Inducible pluripotent stem cell models, TAKO-TSUBO CARDIOMYOPATHY, STRESS-INDUCED CARDIOMYOPATHY, COUPLED RECEPTOR KINASE-5, NERVOUS-SYSTEM, DIAGNOSTIC-CRITERIA, EMOTIONAL-STRESS, MODEL REVEALS, FOLLOW-UP, RAT MODEL, CATECHOLAMINE",
author = "E. Omerovic and R. Citro and E. Bossone and B. Redfors and J. Backs and B. Bruns and M. Ciccarelli and L.S. Couch and D. Dawson and G. Grassi and M. Iacoviello and G. Parodi and B. Schneider and C. Templin and J.R. Ghadri and T. Thum and O. Chioncel and C.G. Tocchetti and {Van der Velden}, J. and S. Heymans and A.R. Lyon",
note = "Funding Information: D.D. acknowledges the support from the British Heart Foundation grants PG/15/108/31928 and FS/16/39/32174, the Josephine Lansdell British Medical Association 2015 Award and Tenovus Scotland, G13.10. S.H. acknowledges the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON2016-Early HFPEF, 2015-10, and CVON She-PREDICTS, grant 2017-21, CVON-Arena-PRIME, European Union Commission's Seventh Framework programme under grant agreement n. 305507 (HOMAGE) and n. 602904 (FIBROTARGETS). A.R.L. is supported by the Leducq Foundation Cardio-Oncology Network. Conflict of interest: none declared. Funding Information: D.D. acknowledges the support from the British Heart Foundation grants PG/15/108/31928 and FS/16/39/32174, the Josephine Lansdell British Medical Association 2015 Award and Tenovus Scotland, G13.10. S.H. acknowledges the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON2016‐Early HFPEF, 2015‐10, and CVON She‐PREDICTS, grant 2017‐21, CVON‐Arena‐PRIME, European Union Commission's Seventh Framework programme under grant agreement n. 305507 (HOMAGE) and n. 602904 (FIBROTARGETS). A.R.L. is supported by the Leducq Foundation Cardio‐Oncology Network. Publisher Copyright: {\textcopyright} 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.",
year = "2022",
month = feb,
doi = "10.1002/ejhf.2368",
language = "English",
volume = "24",
pages = "274--286",
journal = "European journal of heart failure",
issn = "1388-9842",
publisher = "John Wiley & Sons Inc.",
number = "2",
}